



Genetics As A Cause Of Mental Illness Disability

BY: LIZ SCOTT

Mental illness and the resultant disability can have dramatic human and financial cost. Scientists hypothesize that genetics plays a role in mental illness conditions. They cannot pinpoint one gene that causes mental illness, but contemplate interactions. The consensus is that mental illness is triggered by a significant stressful situation resulting in complex interactions among multiple genes in multiple brain and body pathways.

We at Organizational Solutions are not scientists, we are disability case managers with a strong focus on understanding mental illness and recovery. We have concluded that based on the data collected over thousands of claims that genetics can play a significant role in mental illness. In examining disability cases, we can see that mental illness is significantly affected by an individual's genetic makeup.

For the first time in 2016, we encountered pharmacogenomics as an emerging solution when individuals were struggling with mental health conditions. We took an interest in the science in the hope that it may be able to help people with mental illness. The science promised that a genetic saliva test could help determine the best medication for a person with the least side effects.

We spoke to several providers and we

selected Personalized Prescribing Inc. (PPI). Our decision was driven by science, and its use of pharmacists to interact with patients to do a health history interview, ensure an understanding of the science, and explain how it could assist.

We commenced utilizing its services for mental illness cases. Our recovery facilitators would decide if a case may qualify, obtain an agreement from the employer to spend the money, and then refer the patient.

In the beginning, we had issues getting individuals to understand that a pharmacogenomics test may assist in ensuring the best medication match. A suggestion was made that we request that the patients speak to the pharmacists to educate them on the test and science. This approach made a big difference.

Pleasantly Surprising

The results were pleasantly surprising; almost every patient was satisfied with the service. In many cases, the medication change worked wonders, with many patients reporting that they felt much better, and most have returned to work. The physicians overall accepted the pharmacist's recommendations and appreciated the contribution it made to their patient's outcomes.

OSI was intrigued with the outcomes and requested some data to determine the success of the program. We learned almost every patient we referred had many genetic

variants that impacted the efficacy and side effects of mental illness medication. The information was quantified through a genetic mutation score (GMS) and morbidity score.

The GMS is an absolute number, but the morbidity score is not. The GMS is an indication of the variations in the genes that play a role in drug response. In mental illness, there are two main metabolism genes, the CYP2C19, and the CYP2D6. There is also a cascade of drug neurotransmitter genes, each playing a small role in impacting a drug's effectiveness and side effects. The morbidity score is a self-reported score by the patient per the pharmacist that dealt with that patient.

A score of five is attributed for each of the metabolic genes, with zero for normal metabolizers, two for intermediate, and five for poor or ultra-rapid metabolizers. They attributed a score of zero for drug neurotransmitter genes that are all normal and five for many mutated drug neurotransmitter genes (See *Exhibit 1*).

A patient with a GMS of five points or more is more likely to encounter challenges in being prescribed the correct medication. The higher the score, the bigger the challenge.

The morbidity score is a measure of the severity of the patient's case. They scored zero for no side effects and five for multiple and/ or severe side effects, and self-reporting by the patient on how they feel from zero to five. Individual mutation

